The report highlights the significant increase in the adoption of crizotinib in the pharmaceutical industry, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the crizotinib market.
The crizotinib market is bifurcated into capsule and application. Based on capsule, the market is segmented into 250mg capsule and 200mg capsule. In 2022, the 250mg capsule segment dominated in the overall crizotinib market. Based on application, the market is categorized into ALK-positive NSCLC and ROS1-positive NSCLC. In 2022, the ALK-positive NSCLC segment accounted for the highest market share in the crizotinib market.Get Free Sample
|200mg capsule and 250mg capsule
|ALK-positive NSCLC and ROS1-positive NSCLC
|North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
The market is dominated by certain major companies such as Pfizer, Incepta Pharmaceuticals Ltd, and MANUS AKTTEVA BIOPHARMA LLP., among others which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the crizotinib market is expected to witness substantial growth in the coming years due to the rise in the adoption of crizotinib for lung cancer treatment.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.